ArrowMark Colorado Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

ArrowMark Colorado Holdings’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-64,000	Closed	-$4.44M	–	323
2019 Q1	$4.44M	Hold	64,000	–	–	0.04%	219
2018 Q4	$2.78M	Hold	64,000	–	–	0.03%	251
2018 Q3	$4.89M	Hold	64,000	–	–	0.04%	235
2018 Q2	$4.92M	Hold	64,000	–	–	0.05%	237
2018 Q1	$3.26M	Buy	+64,000	New	+$3.22M	0.03%	239
2014 Q2	–	Sell	-5,586	Closed	-$273K	–	354
2014 Q1	$273K	Buy	+5,586	New	+$288K	0.01%	276

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ArrowMark Colorado Holdings's RARE Position: Q2 2019 in Review

ArrowMark Colorado Holdings sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2019, closing a stake of 64,000 shares — an estimated $4.44M sold.

ArrowMark Colorado Holdings first reported a position in RARE in Q1 2014 and held it in 6 quarters. The position peaked at $4.92M in Q2 2018. 170 funds tracked by Wall St. Rank hold RARE as of Q2 2019.

ArrowMark Colorado Holdings reported no remaining Ultragenyx Pharmaceutical position as of Q2 2019 after selling out during the quarter.
ArrowMark Colorado Holdings sold 64,000 Ultragenyx Pharmaceutical shares in Q2 2019, an estimated $4.44M.
ArrowMark Colorado Holdings first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 6 quarters.
ArrowMark Colorado Holdings's Ultragenyx Pharmaceutical position peaked at $4.92M in Q2 2018.
170 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2019.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.